In the current issue of Clinical and Translational Gastroenterology (CTG), researchers published results of a clinical trial that explored lubiprostone and its effect on mucus, mucus secretion and viscosity. Learn the results of their trial. CTG, published on behalf of the ACG, is a peer-reviewed, open-access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology.
Lubiprostone is an effective treatment for opioid-induced constipation, according to a study of patients who used the drug for nine months. Researchers said participants showed increased spontaneous bowel movement frequency, and they reported improvements in degree of straining, stool consistency, constipation severity, and bloating and discomfort.
Lubiprostone has gained widened FDA approval, making it the first oral therapy approved for opioid-linked constipation in adults who have chronic, noncancer pain. The drug was previously approved for chronic idiopathic constipation among adults and constipation associated with irritable bowel syndrome in adult women.
A Phase III study of lubiprostone showed it was safe for patients with irritable bowel syndrome and constipation who took it twice daily for 36 weeks. Marketed as Amitiza by Sucampo Pharmaceuticals and Takeda Pharmaceutical, the drug is indicated for chronic idiopathic constipation and IBS-C, which often require long-term treatment.
A small dose of the chronic constipation drug lubiprostone can alleviate the constipation associated with IBS, according to two new studies involving more than 1,000 people. The benefits were seen using a third of the dose used to treat chronic constipation.